The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...

Meena Seshamani believes the landmark Inflation Reduction Act will “lay the foundation” for future drug price negotiations ...

RTW forms Prolium to develop Keymed Biosciences' CD20×CD3 bispecific CM355 outside Asia for $17.5M upfront, part of growing ...

Welcome back to the new and improved Endpoints Weekly! This week we’ll be recapping the JP Morgan Healthcare Conference, IRA ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...